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Abstract
Background: Growth factor, cytokine and chemokine-induced activation of PI3K enzymes constitutes the start
of a complex signalling cascade, which ultimately mediates cellular activities such as proliferation, differentiation,
chemotaxis, survival, trafficking, and glucose homeostasis. The PI3K enzyme family is divided into 3 classes; class
I (subdivided into IA and IB), class II (PI3K-C2α, PI3K-C2β and PI3K-C2γ) and class III PI3K. Expression of these
enzymes in human tissue has not been clearly defined.
Methods: In this study, we analysed the immunohistochemical topographical expression profile of class IA (antip85 adaptor) and class II PI3K (PI3K-C2α and PI3K-C2β) enzymes in 104 formalin-fixed, paraffin embedded
normal adult human (age 33–71 years, median 44 years) tissue specimens including those from the gastrointestinal,
genitourinary, hepatobiliary, endocrine, integument and lymphoid systems. Antibody specificity was verified by
Western blotting of cell lysates and peptide blocking studies. Immunohistochemistry intensity was scored from
undetectable to strong.
Results: PI3K enzymes were expressed in selected cell populations of epithelial or mesenchymal origin.
Columnar epithelium and transitional epithelia were reactive but mucous secreting and stratified squamous
epithelia were not. Mesenchymal elements (smooth muscle and endothelial cells) and glomerular epithelium were
only expressed PI3K-C2α while ganglion cells expressed p85 and PI3K-C2β. All three enzymes were detected in
macrophages, which served as an internal positive control. None of the three PI3K isozymes was detected in the
stem cell/progenitor compartments or in B lymphocyte aggregates.
Conclusions: Taken together, these data suggest that PI3K enzyme distribution is not ubiquitous but expressed
selectively in fully differentiated, non-proliferating cells. Identification of the normal in vivo expression pattern of
class IA and class II PI3K paves the way for further analyses which will clarify the role played by these enzymes in
inflammatory, neoplastic and other human disease conditions.
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Background
Phosphatidylinositol 3-kinases (PI3Ks) were first identified as enzymes associated with various oncoproteins and
growth factor receptors [1]. Evidence soon accumulated
that PI3Ks can provide a critical signal for cell proliferation, cell survival, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, and
superoxide production as well as actin reorganization and
chemotaxis [2,3]. The diverse range of PI3K functional
effects reflects its activation by multiple receptors, the
existence of a PI3K enzyme family, and multiple effector
proteins that can interact with PI3K lipid products by distinct structural motifs [4]. Mammalian PI3Ks are divided
into three classes based on their structure and substrate
specificity [5]. Class I enzymes are acutely activated by a
variety of cell-surface receptors, and are responsible for
synthesis of intracellular phosphatidylinositol (3,4,5)-trisphosphate (PtdIns (3,4,5) P3) [4]. Class I PI3Ks are
divided into two types. Class IA consists of a p110 catalytic subunit that associates with an SH2 domain-containing subunit: p85 (and its splice variants: p55 and p50).
The p85 subunit is considered the most abundant of the
class IA regulatory subunits. The majority of tyrosine
kinase coupled transmembrane receptors can activate
class IA PI3K, although there is a clear variation in the
strength and duration of the resulting signals [2]. The only
class IB PI3K identified to date is the p110γ catalytic subunit complexed with a p101 regulatory protein and activated by heterotrimeric G proteins. Class IB PI3K is largely
observed in white blood cells [6] with some expression in
murine prostate, kidney, exocrine pancreas and salivary
glands [7]. PI3K-dependent accumulation of PtdIns
(3,4,5) P3 initiated a multitude of downstream signals
that include suppression of apoptosis, reorganization of
the actin cytoskeleton, cardiac myocyte growth, glycogen
synthase stimulation by insulin, TNF-mediated neutrophil priming and superoxide generation, and leukocyte
migration and adhesion to endothelial cells [2,8]. In contrast to class I PI3Ks, which are mainly cytosolic, class II
PI3Ks are predominantly associated with membrane fractions of cells [4]. Enzymes of this class are larger than class
I or III PI3Ks, bind adaptor proteins via proline rich
regions present within their N-terminal sequence [9]. The
association of class II PI3K enzymes with cellular membrane compartments might suggest participation of these
enzymes in sorting events or vesicle formation [10]. However, it has recently become evident that a variety of membrane receptors, including tyrosine kinases [insulin,
epidermal growth factor receptor (EGFR), platelet derived
growth factor receptor (PDGFR)] integrins and a chemokine, monocyte chemotactic peptide-1 (MCP-1), can activate the class II kinases [11–13]. Based on work with cell
lines and Northern blotting, expression of PI3K-C2α,
PI3K-C2β isoforms was considered ubiquitous [14,15],
whilst PI3K-C2γ was mainly found in the liver [16,17].
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Class III PI3K is homologous to the saccharomyces cervisiae Vps34p. It is a constitutively active enzyme whose
product phosphatidylinositol-3-phosphate (PtdIns (3) P)
plays an essential role in protein trafficking through the
lysosome [18].
Extensive insight into the PI3K signalling network has
been gained through the use of PI3K inhibitors, overexpression approaches, gene targeting studies and microinjection of PI3K antibodies into cells [2,4,19]. Whilst these
methodologies have assigned roles for PI3K enzyme activity, there is little evidence for critical non-redundant functions of individual enzyme subclasses. Fundamental to
the understanding of PI3K enzyme specificity is therefore
a robust definition and comparison of the pattern of PI3K
expression in human tissues. The existence of multiple
classes of PI3K enzymes and several isoforms within each
class (class IA/IB, PI3K-C2α, PI3K-C2β, PI3K-C2γ) suggests significant signalling redundancy potentially manifesting in tissue/cell type specific expression.
Identification of tissues in which individual or multiple
PI3K isoforms are expressed could provide clues to the
role or regulation of PI3K enzymes in vivo and identify
more relevant in vitro systems to study these enzymes. Furthermore, recognition of PI3K tissue expression has clinical relevance as it would assist in developing targeted
therapies utilising PI3K inhibitors.
In this study, we analyze and describe the topographical
and semi-quantitate the level of expression of three PI3K
isoforms (IA PI3K (p85), PI3K-C2α and PI3K-C2β),
which are considered to be widely distributed (data based
on in vitro studies), in a range of normal human tissues
using immunohistochemical techniques.

Methods
Tissue Specimens
The study was approved by the Hammersmith, Queen
Charlotte's and Chelsea hospitals research ethics committee. A total of 104 adult normal human tissues specimens
from the gastrointestinal (GI), respiratory, reproductive
and genitourinary tracts were investigated for the expression of PI3K enzymes. Samples were obtained from the
archives of the Department of Histopathology, Hammersmith Hospital, London. 4 µm thick serial sections were
cut and mounted on Vectabond™-coated slides for
immunohistochemistry.
Antibodies
Expression of class I PI3K was investigated using an antiPI3K monoclonal antibody (anti-p85) (BD Biosciences
(Lexington, KY)) and for PI3K-C2α and PI3K-C2β, polyclonal rabbit antisera were generated as described previously [11,14]. Briefly, N-terminal fragments of PI3K-C2α
and PI3K-C2β were expressed as GST fusion proteins and
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used immunize rabbits at monthly intervals. One week
after each injection, serum was obtained and its ability to
immunoprecipitate and Western blot its corresponding
protein was confirmed. For this study, each antibody was
affinity purified using the respective fusion protein crosslinked onto glutathione-sepharose beads. To deplete antiGST reactive antibodies, each eluate was incubated with
an excess of GST immobilised on glutathione sepharose
beads and the supernatant recovered.
Anti-CD68 (PG-M1) (Dako, Denmark) was used in
selected sections to identify macrophages in mononuclear
cell populations.
Immunohistochemistry (IHC)
Before embarking on the study, dilution curves, microwave antigen retrieval schedules and enzymatic digestions, were determined for all antibodies used in this
study (data not shown). Routinely formaldehyde-fixed,
paraffin embedded tissues were deparaffinized, rehydrated in graded alcohols, and stained using the avidinbiotin immunoperoxidase method. Antigen retrieval was
performed for 15 min in 10 mM citrate buffer (pH 6) on
all sections either in a microwave oven (Whirlpool 750
watts) for anti-p85 antibody or in an autoclave (Prestige
Medical, UK) for the class II PI3K antibodies. Sections
were allowed to cool at room temperature and endogenous peroxidase was blocked by 0.03% H2O2. In the case
of PI3K-C2 antibodies, serum blocking (normal goat
serum (DAKO, Denmark)) and avidin-biotin blocking
(Vector laboratories, USA) preceded the application of
primary antibodies. The primary antibodies were diluted
in PBS (Phosphate buffered saline (PBS pH 7.2+/-0.2 containing 0.1%BSA/0.1% sodium azide) p85 (1 µg/ml),
PI3K-C2α (1:400) and PI3K-C2β (1:600) and incubated
overnight at 4°C. To detect p85 expression, the DAKO
Envision™ Kit was used according to the manufacturer's
instructions while a secondary goat anti-rabbit antibody
(DAKO) followed by avidin-biotin peroxidase (Vector
Elite ABC kit, Vector Laboratories, Inc., Burlingame, CA)
were used for detection of PI3K-C2. Reactivity was visualised using 3' diaminobenzidine (DAB), which produces a
brown reaction product and then lightly counterstained in
haematoxylin. Control slides, where the primary antibody
was substituted with PBS or diluted non-immune mouse
or rabbit IgG were checked for non-specific reactivity
before assessment of the staining intensity and percentage
of positive cells.
Determination of class II PI3K antibody specificity
PI3K antibodies were used for Western blotting on cell
lysates prepared from breast (MCF-7, T47D) and prostate
(CWR22Rv1, LNCaP, PC3 and DU145) cancer cell lines as
previously described [9]. Dilutions used were 0.1 µg /ml
for p85 and 0.4 µg/ml for anti-class II PI3K antibodies. To
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confirm the specificity of the immunoreactive signal
detected by IHC, serial dilutions of the PI3K-C2α peptide
fragment (0.05–0.2 mg/ml) and the PI3K-C2β peptide
fragment (0.08–0.5 mg/ml) were pre-incubated with their
corresponding antibody for 2 hours at room temperature
prior to immunostaining. To exclude reactivity with the
GST fusion fragment of the antigenic peptide, antibodies
were pre-incubated with GST prior to IHC. PI3K-C2α was
pre-incubated with excess of PI3K-C2β peptide and vice
versa to identify cross-reactivity between the PI3K-C2 antibodies. As an additional control, an irrelevant peptide
(COX-2 peptide (Cayman Chemical, USA) 0.05–0.5 mg/
ml) was pre-incubated with the class II antibodies prior to
staining of sections.
Assessment of Immunoreactivity
Intensity of PI3K immunoreactivity was quantified by two
independent investigators (SES and PT) using a visual
scoring scale (- undetectable; + weak; ++ moderate; +++
strong). The distribution of staining was considered membranous, cytoplasmic or nuclear, homogenous or heterogenous. In case of cytoplasmic expression, diffuse or
granular appearance was recorded. Photomicrographs
were captured using a DP12 Olympus camera (Olympus,
UK) fitted on a Leitz Dialux 22 microscope (Leica
microsystems, UK) at the indicated magnification.

Results
Confirmation Of Antibody Specificity
Each of the three antibodies recognised a single protein
band of the appropriate size on Western blotting (Figure
1A). Neither of the class II PI3K antibodies have previously been assessed for their reactivity on fixed human tissues. To
verify
the specificity of
PI3K-C2
immunoreactivity, blocking studies were performed by
pre-incubation of each antibody with the protein fragment used to raise it prior to its application in IHC. This
abolished class II PI3K antibody staining (Figure
1B,1C,1D,1E). Pre-incubation with equivalent concentrations of GST or an irrelevant peptide had no effect on
immunostaining confirming specificity to each N-terminal PI3K-C2 sequence. Pre-incubation of PI3K-C2α antibody with N-terminal PI3K-C2β protein or PI3K-C2β
antibody with N-terminal PI3K-C2α protein (at concentrations which completely blocked staining from its
corresponding antibody) did not reduce the intensity of
staining with antibody (data not shown). Negative control sections incubated with non-immune IgG or PBS were
included with each experiment and were consistently
negative.
PI3K Expression Profile in Normal Human Tissues
Expression of the class I p85 adaptor and class II PI3K
were assessed in 104 normal adult human samples using
the above antibodies. Expression of these enzymes was
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tide
Specificity
fragments
1 of immunohistochemical detection of the PI3K-C2 enzymes using antibodies raised against class II N-terminal pepSpecificity of immunohistochemical detection of the PI3K-C2 enzymes using antibodies raised against class II
N-terminal peptide fragments. Lysates from breast (MCF-7 and T47D, lanes 1 and 2) and prostate (CWR22Rv1, LNCaP,
PC3 and DU145 cells, lanes 3–6 respectively) cancer cell lines were probed for PI3K antibodies (p85, PI3K-C2α and PI3KC2β). Molecular weight markers in KDa are indicated on the left. In the lower panels, representative PI3K-C2α and PI3K-C2β
labelled sections with (B and D respectively) or without pre-absorption of each antibody with its antigenic peptide (0.1mg/ml
of N-terminal PI3K-C2α in C and 0.5mg/ml of N-terminal PI3K-C2β in E) are presented. Original magnification (A-D × 200).

Page 4 of 14
(page number not for citation purposes)

BMC Clinical Pathology 2003, 3

http://www.biomedcentral.com/1472-6890/3/4

Table 1: PI3K expression patterns in normal human tissues.

Human Tissues

n

Digestive system
Stomach

3

Small intestine

7

Colon

10

Features common to all GIT

Respiratory system
Lung

5

Bronchi

Skin and Integument

5

Female reproductive system
Uterus

Cervix

3
3

3

Ovary

3

Fallopian tube
Mammary gland (breast)

2
3

Male reproductive system
Testis

3

Prostate gland

10

Histological Structure

p85

PI3K-C2α

PI3K-C2β

Figure

Peptic (chief) cells
Parietal (oxyntic) cells
Gastric mucous cells
Enterocytes
Paneth cells
Goblet cells
Colonocytes
Goblet cells
Mononuclear cells
Muscular layers
Ganglion cells
Non-myelinated nerves
Neuroendocrine cells

+++
+++
++
++
+++
+++
-

++
++
++
++
++
-

++
+
++
+++
+++
++
-

2A

Pneumocytes (Types I and II)
Alveolar Macrophages
Bronchial Epithelium
Bronchial glands
Cartilage
Bronchial smooth muscle
Stratified squamous epithelium
Melanocytes
Sebaceous glands
Hair follicle
Sweat Glands
Langerhans cells
Dermal macrophages

++
+
+
+
+
++
++

++
+
++
+
++

++
+
++

Proliferative Endometrium
Secretory Endometrium
Endometrial Stroma
Myometrium
Ectocervical squamous epithelium
Endocervical glands
Cervical smooth muscle
Follicular cells
Germinal cells
Stromal cells
Corpus luteum
Columnar ciliated epithelium
Luminal acinar epithelium
Myoepithelial cells
Lactiferous ducts

++
+
++
ND
+++
-

++
++
+
ND
++
+
+

+
ND
+
-

Spermatogenic cells
Sertoli cells
Leydig cells
Basal Epithelium
Luminal epithelium
Fibromuscular stroma

+++
++
-

+++
+
++

+++ *
++
-

2P, 2Q *

Transitional epithelium
Muscularis
Glomerular macrophages
Glomerular tuft
Proximal Tubules
Macula Densa
Distal tubules

++
++
++
-

++
++
+++
+
+

++
++
+
+

2R

2B

2C
2D
2E
2E

2F

2G
2G
2H
2H
2I
2I
2J
2K

2L
2M

2N
2O

Urinary system
Urinary bladder

5

Kidney

10

3A
3B
3A
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Table 1: PI3K expression patterns in normal human tissues. (Continued)

Pancreas

5

Hepatobiliary system
Liver

4

Gall bladder

4

Endocrine System
Thyroid
Parathyroid
Endocrine Pancreas
Lymphoid tissue & Immune cells
Spleen

Lymph nodes

Collecting tubules
Acini
Ducts
Islets of Langerhans

+++
+++
-

+
++
++
-

+
-

Hepatocytes
Bile ducts
Kupffer cells
Lining epithelium
Smooth muscle layer
Mononuclear cells

+
++

++
+
++
++

+
++

-

-

-

++
++

+
+++
+

++
+

++
+++
+

+
++
+++

++
++
-

3
3

Follicular/Parafollicular
Oxyphil/Chief
Islets of Langerhans

5

White pulp
Red pulp (mononuclear cells)
Red pulp (splenic sinusoids)
Lymphoid follicles
Germinal centre mononuclear
cells
Medulla (mononuclear cells)
Tissue macrophages
Polymorphnuclear leucocytes

5

3C, 3D
3D
3C

3E
3F

3G
3H

Abbreviations and symbols used: ND: Not determined; - undetectable; + weak; ++ moderate or +++ strong. Reactivity for PI3K-C2α in venous and
capillary endothelium was not included in the tissue staining results. *Expression of PI3K-C2β was nuclear in spermatocytes.

found in many cell types and tissues (summarised in
Table 1). In positive cells, expression was mainly cytoplasmic and occasionally membranous whereas cell nuclei
only stained with PI3K-C2β (in the testis). p85, PI3K-C2α
and PI3K-C2β were expressed in columnar and transitional epithelia while mucous secreting and stratified
squamous epithelia were negative. Mononuclear cells in
the lamina propria, dermis, submucosae of different tissues expressed p85, PI3K-C2α and PI3K-C2β. The majority of mononuclear cells were of the macrophage lineage
as confirmed by staining of serial sections with CD68.
Smooth muscle cells expressed PI3K-C2α in different
organs investigated (vessels, muscularis layer of the GI
tract, urinary tract, uterus, fallopian tubes and prostate)
but expression was distinctly fainter than that observed in
epithelial cells. Endothelial cells lining capillaries and
small venules frequently expressed PI3K-C2α. The patterns of expression in the different body systems are
detailed below:
Gastrointestinal (GI) tract
In the stomach, immunoreactivity for each PI3K antibody
was limited to the basal third of the fundic glands where
peptic (chief/zymogenic cells) predominate (Figure 2A).
Expression was cytoplasmic coarse and granular. Along
the crypt/villus axis of the small intestine, p85, PI3K-C2α
and PI3K-C2β were expressed in enterocytes covering the

intestinal villi while Paneth cells expressed only p85 (Figure 2B). Expression was cytoplasmic, coarse granular with
p85 and diffuse for class II PI3K. In the colon and appendix, PI3K enzyme expression was observed in colonocytes.
Mucous-secreting (gastric surface and neck mucous cells ;
intestinal goblet cells and Brunner glands), neuroendocrine, and stromal cells of the lamina propria were
negative.
Macrophages and other mononuclear cells found in the
lamina propria expressed p85 PI3K-C2β and to a lesser
extent PI3K-C2α. Lymphoid follicles were negative for all
three enzymes with occasional positivity in germinal
center macrophages (Figure 2D). Strong expression of p85
and PI3K-C2β but not PI3K-C2α was observed in the Ganglion cells in the parasympathetic ganglia of the submucosal (Meissner's) and myenteric (Auerbach's) plexus.
PI3K-C2β was found in the unmyelinated nerve fibres
penetrating between the smooth muscle fibres (Figure 2E)
and myelinated peripheral nerves in the vicinity of major
vessels.
Respiratory tract
Neither the squamous (type I) nor the cuboidal (type II)
pneumocytes expressed p85 or Class II PI3K enzymes. In
contrast, all three PI3K enzymes were expressed in scattered alveolar macrophages (Figure 2F) and in the columPage 6 of 14
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A

B

C

D

E

F

GC

PI3K-C2E

PI3K-C2E

G

H

I

J

K

L

N

O

Q

R

M
G

T

P

Sp
Sp

PS
S

PS

S
PI3K-C2E

Figure
Representative
2
sections of p85 and PI3K-C2β (E, F and Q) expression in adult human tissues
Representative sections of p85 and PI3K-C2β (E, F and Q) expression in adult human tissues. In the GI tract,
expression was observed in the lower third of gastric glands (A), in villous enterocytes (B), in surface colonocytes (C) and in
macrophages infiltrating the lamina propria, especially in the appendix (D). Note the lack of expression of p85 in reactive germinal centres (GC) or in mature B lymphocytes. Myenteric plexuses and unmyelinated nerves (arrow heads) penetrating
smooth muscles expressed PI3K-C2β as shown (E). PI3K-C2β was strongly expressed in alveolar macrophages in the lung
(marked by arrows) (F). In the skin, p85 reactivity was observed in sebaceous glands (G), in hair follicles (H) and in Langerhans
cells (I). Luminal p85 immunoreactivity, which was observed in endometrial glands in the proliferative phase (J) gradually disappeared when the secretory phase developed to remain only on the surface (K). In the cervix (L), and breast (O) only infiltrating
macrophages expressed p85, serving as an internal positive control. In the ovarian follicle, p85 expression was seen in granulosa and theca cells (M). Columnar ciliated fallopian tube epithelium was strongly reactive for p85 (N). In the testicular seminiferous tubules, p85 was expressed in the cytoplasm (P) while PI3K-C2β was expressed in the nuclei (Q) of primary
spermatocyes (PS), spermatids (Sp) but not in sertoli cells (S). Transitional epithelium p85 expression was intensified in the
uppermost (umbrella) layer (R). Original magnification (A, B, G, J, N × 100), (C, D, F, H, L, M × 200), (E, F, I, K, O-R × 400).
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nar epithelium lining the bronchioles. PI3K-C2α was
expressed in an apical 'linear' pattern in ciliated cells.
Bronchial mucous glands and cartilage did not express
any of the 3 enzymes studied.
Skin and appendages
Neither enzyme was expressed in keratinised squamous
epithelium or melanocytes. In sebaceous glands, p85,
PI3K-C2α and PI3K-C2β were expressed in acini but not
in germinative cells (Figure 2G). Sweat glands expressed
p85 in luminal secretory cells while PI3K-C2α was
expressed in the myoepithelial layer and in sweat gland
ducts. PI3K-C2β was undetectable in sweat glands (Figure
2H).

At the level of the hair bulb, expression of p85 was barely
detectable. At a higher level, p85 expression was noted in
the companion layer (the innermost layer of the outer
root sheath) and in the cuticle (the innermost layer of the
internal root sheath). Hair matrix cells and follicular
papillae did not express p85 (Figure 2H). PI3K-C2α and
PI3K-C2β were not expressed in the hair follicle. Expression of p85 was observed in a subset of dermal mononuclear cell and Langerhans cells (Figure 2I) while PI3K-C2α
and C2β were expressed in dermal macrophages only.
Female reproductive system
Uterus
The expression of p85 in endometrium varied with the
menstrual cycle. In the proliferative phase, p85 was
observed on the luminal surface of endometrial glands
and heterogeneously on the luminal endometrial surface.
In the secretory phase, p85 expression was attenuated
from the glandular epithelium, now distended with secretion, to be retained only in the surface endometrium (Figure 2J,2K). There was no stromal expression of either
enzyme throughout the cycle. PI3K-C2α and PI3K-C2β
were not expressed in uterine glands. Myometrium and
vascular smooth muscle expressed PI3K-C2α. Squamous
epithelium of the cervix was negative for all 3 antibodies
(Figure 2L).
Ovary and Fallopian tube
Ovarian tissue expressed p85 in granulosa cells of antral
follicles and in theca cells (Figure 2M). PI3K-C2α and
PI3K-C2β were expressed in theca cells only. Ovarian surface epithelium, rete ovarii and corpora lutei did not
express PI3K. In the stroma, scattered positive macrophages were observed. Fallopian tube expressed p85 (Figure 2N), PI3K-C2α and PI3K-C2β in the cytoplasm of
lining ciliated columnar epithelium. Whereas p85 and
PI3K-C2β were expressed diffusely, PI3K-C2α was mainly
expressed in a linear pattern beneath the cilia.
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Breast
Normal breast lobules expressed no p85 (Figure 2O),
PI3K-C2α or PI3K-C2β. In areas of apocrine metaplasia,
weak expression of p85 was noted. Myoepithelial cells
occasionally expressed PI3K-C2α, which was also weakly
expressed in normal ductal epithelium.
Male reproductive system
Testis
Germ cells in the basal and intermediate compartments of
the seminiferous tubule, namely the spermatogonium,
pre-leptotene, leptotene and zygotene spermatocytes,
expressed weak p85 and PI3K-C2β. In the developmental
stages extending from pachytene spermatocytes to elongating spermatids, reactivity for p85 (Figure 2P) was
detected in the cytoplasm and for PI3K-C2β in the nuclei
of germ cells. Strong p85 expression was found in secondary spermatocytes and this was maintained in mature
spermatozoa. Spermatogonia lacked p85 and PI3K-C2β
while final differentiating sperm were devoid of PI3K-C2β
expression (Figure 2Q). No expression of PI3K-C2α was
observed with spermatocytic maturation. In contrast to
interstitial Leydig cells, in which weak heterogeneous
expression of p85, PI3K-C2α and PI3K-C2β was observed,
sertoli cells were not reactive for either antibody.
Prostate
Normal prostatic glands in the clinical setting of benign
prostatic hyperplasia (BPH) did not express any p85 or
PI3K-C2β. PI3K-C2α was expressed in an interrupted
manner in basal (myoepithelial) prostatic cells and in
prostatic fibromuscular stroma.
Urinary tract
In transitional epithelium, p85 and PI3K-C2β expression
was generally strong in the cytoplasm of superficial cells
and weak in the intermediate and basal cells (Figure 2R).
Expression was heterogenous and scattered negative
superficial cells were observed. Smooth muscle bundles
and endothelium expressed PI3K-C2α.

In the kidney, macrophages (confirmed by reactivity for
CD68) were the only cells in the glomeruli, which
expressed p85 and PI3K-C2β (Figure 3A). Expression of
PI3K-C2α in the glomerular tuft was observed in the parietal layer of Bowman's capsule being reflected on and in
continuity with reactivity in the visceral (podocyte) layer.
It appeared to be distinct from glomerular endothelial lining as demonstrated in Figure 3B. In the renal tubules,
cytoplasmic expression of p85 was seen in the macula
densa and in collecting tubules (Figure 3A). PI3K-C2α
and PI3K-C2β were weakly expressed in proximal, distal
and collecting tubules and ducts.
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Contrasting
immune
(G, H)
of p85 (left panels) and PI3K-C2α (right panels) in the kidney (A, B), pancreas (C, D), spleen (E, F) and
Contrasting expression of p85 (left panels) and PI3K-C2α (right panels) in the kidney (A, B), pancreas (C, D),
spleen (E, F) and immune cells (G, H). In the kidney, p85 was expressed in glomerular macrophages (see inset) and in the
macula densa (MD) (A) while PI3K-C2α labelled the glomerular tuft (B). Closer examination of the marked area (inset),
expression is observed to be epithelial (P) rather than endothelial (C) or mesangial (M). Pancreatic acinar cells expressed p85
in a cytoplasmic subnuclear position(C) while PI3K-C2α highlighted intercalated ducts (D). Mononuclear cells (macrophages) in
the splenic red pulp were reactive for p85 (E). PI3K-C2α was observed in macrophages and in splenic sinusoids, in an interrupted bead-like manner (F). Acute inflammatory cells (arrow head) adhering to the wall of a dilated capillary (C) are not reactive for p85 (G) but express PI3K-C2α (H). Tissue macrophages expressed p85 (membranous expression is marked by
arrows) and cytoplasmic PI3K-C2α. (Original magnification A, C, D and E × 400), (B × 200), (F-H × 1000)
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Pancreas and Hepatobiliary tract
Heterogenous cytoplasmic expression for p85 and PI3KC2α was noted in the exocrine component of the pancreas
with no detectable immunoreactivity in islets of Langerhans' cells. The class I (p85) enzyme was expressed in the
acinar cytoplasm in a subnuclear basal position (Figure
3C) while PI3K-C2α was expressed on the luminal border
of the acinus corresponding to the intercalated ducts (Figure 3D). Pancreatic ducts (intralobular, interlobular and
the larger ducts) only expressed PI3K-C2α. PI3K-C2β was
not observed in the pancreas.

Hepatocytes, hepatic sinusoids and Kupffer cells did not
express detectable levels of p85, PI3K-C2α or PI3K-C2β.
PI3K-C2α immunolabeled bile ducts. In the gall bladder,
the lining epithelium was reactive for all three antibodies.
Thyroid and Parathyroid glands
No immunoreactivity for p85, PI3K-C2α and PI3K-C2β
was detected in thyroid glands (follicular or parafollicular
cells) or parathyroid glands (chief/principal) cells and
oxyphil cells).
Lymphoid tissue and immune cells
In lymph nodes and in the spleen, p85 and PI3K-C2β
reactivity was limited to a few cells in the interfollicular
and medullary areas (Figure 3E). Endothelial cells lining
venous sinusoids in the spleen expressed PI3K-C2α in a
subnuclear position forming an interrupted linear, almost
bead-like pattern (Figure 3F). p85, PI3K-C2α and PI3KC2β labeled individual tissue macrophages (Figure 3G)
and follicular dendritic cells in the germinal center but
were not expressed in the B lymphocyte precursors or
mature B cells (Figure 2D). Only PI3K-C2α was detected
in significant levels in polymorphnuclear leucocytes (Figure 3G,3H).

Discussion
Most of the current literature relies on biochemical methods to provide evidence for the presence of PI3K mRNA or
protein in human tissue or cell line lysates [14–16]. With
a single report of p85 expression (in lung cancer) [20] and
none relating to PI3K-C2α and PI3K-C2β, there was a
need for a systematic study examining topographical
expression and precise cellular localisation of PI3K
enzymes in human tissues.
Our report illustrates the selective expression of PI3K
enzymes in normal adult human tissues, appearing to be
restricted to the differentiated cell lineages compared to
the proliferative and stem cell compartments. In differentiated cells (epithelial and mesenchymal), expression of
p85, C2α and C2β, either singly or in combination, was
observed only in a limited repertoire of cells. Differences
in expression and in spatial localisation of PI3K isoforms
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possibly reflect the diverse roles played by these enzymes
in various tissues in response to different ligands. In hepatocytes, endocrine organs (thyroid and parathyroid glands
and Islets of Langerhans), squamous epithelium and
secretory epithelia in general, no p85 or class II PI3K
enzymes were detected. This either reflects very low levels
of expression under normal in vivo conditions (not detectable by methods employed in this study), or the predominance of alternative PI3K isoforms in these tissues. In the
liver, for example, there is biochemical evidence of high
expression of PI3K-p50α and PI3K-C2γ in the liver
[16,17,21]. Marked responsiveness of p50α to insulin
suggests that this adaptor plays an important role in the
activation of hepatic PI3K [21]. Another observation was
that those cells expressing only two PI3K isoforms, coexpression of p85 and PI3K-C2α was not observed (Figures 3 and 4). This, together with the unique expression of
PI3K-C2α in mesenchymal elements (endothelial cells
and smooth muscle cells), myoepithelial and ductal cells
suggests a more specialized role for PI3K-C2α compared
to p85 or PI3K-C2β. Further in vitro biochemical studies
are required to elucidate this role.
PI3K expression was analysed in tissues representative of
self regenerating stem cell systems such as skin, intestines,
bladder, uterine cervix and testis (which normally show
growth and differentiation throughout life), quiescent
(stable) tissues such as parenchymal cells of the liver, kidney, pancreas, vascular endothelial cells and thyroid (tissues that show little growth in adult life but can be driven
to proliferate by an appropriate stimulus), and of nondividing (permanent) terminally differentiated cells that
have no reserve capacity for growth such as neurones
(ganglion cells) and macrophages [22]. In self-regenerating tissues, shedding of epithelial cells is compensated by
a precursor stem cell population that rapidly divides then
selectively differentiates to replace lost cells [23]. Proliferation and differentiation are inversely correlated processes
where differentiation of primitive into more specialized
cells involves increased restriction in proliferative capacity, culminating in cell-cycle exit and arrest [24]. Welldefined stem cell compartments have been identified in
the GI tract, skin and testis (reviewed in [25–27]). In these
organs, p85, PI3K-C2α and PI3K-C2β were only expressed
in fully differentiated cells. With the exception of the apical p85 expression in proliferative endometrium, there
was no identifiable expression of PI3K enzymes in stem/
progenitor or proliferating cell compartments. The
absence of either p85 or class II PI3K immunoreactivity in
germinal centres of reactive lymphoid follicles is consistent with our observation that PI3K enzymes are expressed
in differentiated, committed cells and not in proliferating
or immature cells. PI3K expression in permanent nondividing, non-epithelial cells such as ganglion cells and
macrophages is indicative of a general rather than cell-spe-
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Figure 4 patterns of PI3K enzyme expression in adult human tissues
Overlapping
Overlapping patterns of PI3K enzyme expression in adult human tissues. Co-localisation of the p85, PI3K-α and
PI3K-C2β was more frequently observed than expression of one or 2 of these enzymes. Expression of p85 and PI3K-C2α was
not observed.

cific growth regulatory mechanism. Based on in vitro data
examining cell cycle progression in cell lines and
embryonic stem cells [28–32], we would have predicted
an inverse pattern of expression to what was observed.
Our data suggest an association between PI3K and cellular
differentiation. This association is best demonstrated in
intestinal epithelium and testicular seminiferous tubules,

both of which are models to study the mechanisms of tissue differentiation. In these tissues, spatially organised
stem cell, proliferative and differentiated compartments
create a "gradient" of cell differentiation. In the intestine
and the testis, PI3K expression increased with differentiation. The increase in PI3K expression in these tissues was
more dramatic in the case of p85 than for class II enzymes.
Previous in vitro data linking PI3K activation to differenti-
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ation have been controversial. In the intestine, our data
supports the study by Laprise et al [33] who showed that
PI3K activity promotes intestinal epithelial cell differentiation and contradicts others [34,35] who propose that
PI3K inhibition contributes to intestinal cell differentiation. The expression pattern of p85 observed in the testis
is supported by data from Kissel et al [36] who showed
that Kit-mediated PI3K signalling is critical for the development of male germ cells during the pre-meiotic stages.
When these signals were interrupted, male sterility developed due to failure of germ cell to enter meiosis and
increased apoptosis of primary spermatocytes [36]. Interestingly, we observed nuclear PI3K-C2β immunoreactivity
in developing spermatocytes. This pattern of expression
was confined to the testis. A role for nuclear PI3K signalling has been recently identified [37]. Conditions where
the presence of nuclear PI3K-C2β was identified, were
associated with compensatory rat liver regeneration and
differentiation of HL-60 cell line along granulocytic lineage commitment pathways [38,39]. The significance of
PI3K-C2β expression in the testis and its nuclear localisation is currently unknown.
PI3K expression was observed in immune cells including
macrophages and polymorphnuclear leucocytes. The
intensity of expression in macrophages frequently
exceeded that observed in epithelial cells. Interestingly,
only a subset of CD68 positive macrophages (including
Kuppfer cells) expressed PI3K enzymes. One possible
explanation for this observation is that expression may be
related to a specific phase in macrophage function. We are
currently examining this possibility. Polymorphnuclear
leucocytes expressed moderate-strong PI3K-C2α but not
p85. This may be related to the relative abundance of the
leukocyte-specific class IB PI3K isoform. In vitro observations show that PI3Ks are important regulators of phagocytosis [40]. Class IA and III PI3Ks are thought to act
consecutively in phagosome formation and maturation,
and that their respective products, PtdIns (3,4,5) P3 and
PtdIns (3) P accumulate transiently at different stages
[41]. The involvement of class II PI3Ks, which can also
produce PtdIns (3) P can not be excluded [41]. Although
the exact mechanisms involved in receptor coupling
remain obscure, MCP-1-induced activation of PI3K-C2α
may contribute to some of its cellular responses. More vigorous investigations are needed to determine whether
activation of PI3K-C2α or the related PI3KC2β occurs in
response to other chemokines and to determine the functional significance of class II PI3K activation in macrophages. Unexpectedly, B-lymphocytes and their
precursors were non reactive. A role for p85 in B lymphocyte development and activation was demonstrated in
p85α deficient mice in two independent studies [42,43].
However, the regulation of PI3K activation in p85 α-deficient mice is rather complex. In these knockouts, there is
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reduced expression of all class IA catalytic subunits with
enhanced PI3K-dependent responses following stimulation [44–47]. Therefore, extrapolating from these knockout studies to human lymphocyte function is difficult.
The results presented here in suggest a role of PI3K
enzymes in differentiated cells, however, they do not rule
out a role for these enzymes in proliferation. It is possible
that proliferating cells express PI3K enzymes but at levels
which were undetectable by methods used in this study.
Other more sensitive methods such as real-time PCR
could be employed in future studies to explore the above.

Conclusions
One of the limitations of any IHC study is antibody specificity and antigen preservation. Identifying reliable PI3K
antibodies for use in IHC has been especially challenging.
Several commercially available and in-house class I PI3K
antibodies (p85 or p110) including those used in previous IHC studies [20,48] did not give satisfactory results in
our hands. This was either due to limited sensitivity or
reduced specificity (high background or multiple bands
on the Western blot). We selected 3 PI3K antibodies (class
IA PI3K (p85), PI3K-C2α and PI3K-C2β) that recognised
a protein of the appropriate size on Western blotting and
identified their target in formalin-fixed paraffin embedded tissues. Reactivity in IHC was specific as evidenced by
successful blocking of immunoreactivity by the antigenic
peptide fragments to which the antibodies were raised.
We have demonstrated that, in contrast with their expression in cell lines of differing origins, class IA PI3K adaptor,
p85, and class II PI3K enzymes display a specific and
selective tissue distribution. PI3K enzyme expression in
fully differentiated cells argues against their role in cell
proliferation. Studies have indicated that p85 may act as a
signalling protein independent of p110 [49,50]. It is,
therefore, conceivable that p85 signals detected in this
report reflect p110-related lipid kinase activity and other
p110-unrelated functions. The use of reliable p110 antibodies or novel anti-PtdIns (3,4,5) P3 antibodies [51]
should allow more detailed and comprehensive mapping
of the PI3K enzymes in normal and diseased human tissues, and provide insight into potential therapeutic targets
of isoform specific PI3K antagonists.
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